BIOSTATISTICS IN CLINICAL TRIALS
Kate Francis, Biostatistician (Snr Research Officer)
Murdoch Children’s Research Institute &
Honorary Research Fellow,
Department of Paediatrics, University of Melbourne &
Affiliate Biostatistician,
The Royal Children’s Hospital,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | July 2025
Kate Francis is a biostatistician with the Murdoch Children’s Research Institute (MCRI), an Honorary (Senior Fellow) within Department of Paediatrics, the University of Melbourne and Affiliate biostatistician with Royal Children’s Hospital in Narrm (Melbourne), Australia.
As a biostatistician working in research and clinical settings, she plays a vital role in ensuring all projects adhere to best practice guidelines and are transparently reported. She has served as the lead statistician for the analysis of clinical trials across a broad range of subject areas, including neonatal resuscitation, BCG for allergy and infection, convulsive status epilepticus and her work has been published in the top journals such as The New England Journal of Medicine, JAMA, and The Lancet. Most recently she was awarded the 2025 Excellence in Trial Statistics Award for her work on the PLUSS trial.
Kate is also an expert in the measurement of adolescent health behaviours, determinants, and outcomes and this was recognised with her invitation to be a commissioner for the second Lancet Commission on Adolescent Health and Wellbeing which was recently released at the 2025 World Health Assembly meeting.
Kate believes in the importance of gender equity, diversity, and inclusion and was key team member in helping MCRI achieve bronze accreditation in the Science in Australia Gender Equity (SAGE) program.
Source: Supplied
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
-
Behavioural science in cancer screening, control and communication
Dr Dodd has an established international reputation as a behavioural scientist in cancer control and communication. Since completing her PhD in 2016, Dr Dodd has been awarded a three-year University of Sydney Postdoctoral Research Fellowship (2018-2021) and a three-year Research Fellowship at The Daffodil Centre (current). Dr Dodd is the co-chair of the ‘Strengthening and optimising approaches to cancer prevention, screening, and early detection’ hub at The Daffodil Centre (with more than 130 staff and students).
-
Discovery of RANK Ligand’s role in bone metabolism and the immune system to treat osteoporosis
Emeritus Professor Jack Martin’s research began a discovery cascade that led to the identification of a new protein and the development of a novel and effective drug therapy that is now used worldwide to treat osteoporosis, cancer and other diseases.
